… RNA base-editing platform technologies – Axiomer ® and Trident ® ProQR has been further optimizing the Axiomer ® … this in H2 2022. ProQR achieved proof of concept for the Trident ® technology in several models showing translational … of nonsense mediated decay. Further optimizations of the Trident ® platform for development purposes are ongoing. …
Phase 2/3 pivotal Illuminate trial of sepofarsen for LCA10 enrollment complete with top-line data anticipated in H1 2022
Positive data reported from the Phase 1/2 clinical trial of QR-421a for the treatment of Usher syndrome and non-syndromic retini
Top-line data from pivotal Phase 2/3 Illuminate trial of sepofarsen for CEP290-mediated LCA10 anticipated late Q1/early Q2 2022
Five-target collaboration with Lilly highlights significant potential of ProQR’s Axiomer® RNA base-editing pla
… intravitreal injections in the eye. About Axiomer ® and Trident ® ProQR is pioneering a next-generation RNA … the RNA – an Inosine is translated as a Guanosine (G). Our TRIDENT ® RNA pseudouridylation platform enables the …
Preclinical and translational pipeline program data for AX-0810 for Cholestatic Diseases targeting NTCP and AX-1412 for Cardiovascular Disease targeting B4GALT1 anticipated in 2024, building further momentum toward the clinicAccelerated development of Axiomer™ for CNS ap
Preclinical proof of concept data for the AX-0810 program targeting NTCP for cholestatic diseases presented at ASGCT 27th Annual Meeting – Management to host webinar today at 8:00 am EDT to highlight dataMartin Maier, PhD nominated to Board with Annual General
